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Toxin-coregulated pilus (TCP) is a colonization factor required for cholera infection. It is not a strong
immunogen when delivered in the context of whole cells, yet pilus subunits or TcpA derivative synthetic
peptides induce protective responses. We examined the efficacy of immunizing mice with TCP conjugated to
anti-class II monoclonal antibodies (MAb) with or without the addition of cholera toxin (CT) or anti-CD40
MAb to determine if the serologic response to TcpA could be manipulated. Anti-class II MAb-targeted TCP
influenced the anti-TCP peptide serologic response with respect to titer and isotype. Responses to TcpA peptide
4 were induced with class II MAb-targeted TCP and not with nontargeted TCP. Class II MAb-targeting TcpA
reduced the response to peptide 6 compared to the nontargeted TCP response. Class II MAb-targeted TcpA,
if delivered with CT, enhanced the serologic response to TcpA peptides. The effectiveness of the combination
of targeted TCP and CT was reduced if anti-CD40 MAb were included in the primary immunization. These data
establish the need to understand the role of TCP presentation in the generation of B-cell epitopes in order to
optimize TcpA-based cholera vaccines.
Cholera is an acute diarrheal disease caused by Vibrio cholerae. Following ingestion of contaminated food or water, bacteria colonize the small intestine and secrete cholera toxin
(CT), which is responsible for excessive water loss. A number
of live-attenuated- and killed-whole-cell vaccines have been
tested. None have proven successful enough to prevent cholera
in areas of endemicity (2).
The major virulence factors of V. cholerae are CT and toxincoregulated pilus (TCP) (13, 14; reviewed in reference 16).
TCP, a type 4 pilus, is a homopolymer of 20.5-kDa TcpA pilin
subunits. TCP is immunogenic and a virulence factor of V.
cholerae mediating colonization of the human intestine (27–29,
31, 34). Because of culture conditions, there is little TCP antigen in killed-whole-cell cholera vaccines (27). TCP is not a
“dominant” immunogen upon oral infection or experimental
vaccination of humans (13). In North American volunteers, a
single dose of V. cholerae O1 strain O395 induced a nominal
antibody (Ab) response to TcpA. However, 50% of patients
from an area in which cholera is endemic had immunoglobulin
G (IgG) and IgA Abs specific for TcpA, suggesting that multiple exposures can induce an anti-TCP Ab (13).
Paradoxically, TcpA and peptides derived from it are very
immunogenic and can induce protective Abs when not delivered in the context of a natural infection or vaccination with
intact bacteria (27–29, 34). These anti-TCP Abs provide high
levels of protection against virulent V. cholerae in the infant
mouse assay (27, 28). Similar results were obtained with TcpAspecific monoclonal Abs (MAb), as well as with polyclonal
antisera raised against a synthetic peptide corresponding to a
region of TcpA adjacent to the sequences recognized by the

MAb (28, 29). Results of several experimental approaches
have indicated that domains within the C-terminal region of
TcpA (amino acids 145 to 199) delineated by a single disulfide
bond are directly responsible for the protective Ab response
seen in animals immunized with intact TCP (13, 14, 17, 28, 29).
Three peptides, TcpA4, TcpA5, and TcpA6, induce immune
responses in mice that can protect 50 to 89% of infant mice
against a challenge with 100 times the 50% lethal dose (29).
While synthesis of TcpA peptides and their use as immunogens might be possible, we wanted to investigate the potential
of using intact TcpA as an immunogen with and without additional treatments that might improve TcpA’s immunogenicity. Understanding of the roles of various antigen-presenting
cell (APC) surface molecules and cytokines in modulating immune responses has facilitated the rational development of
vaccination strategies. Collectively these treatments, which can
manipulate the immune response, we define as biological response modifiers (BRM). In our study, we focused on three
BRM: CT, class II MAb targeting of antigen, and CD40 ligation. CT enhances the immunogenicity of relatively poor mucosal immunogens (6, 18). Targeting vaccine antigens to class
II molecules enhances access of APCs to antigen and links
signals from the targeted molecules to the temporal acquisition
of antigen (9, 24, 35). CD40 ligation on dendritic cells (DCs)
and B cells is known to modify immune responses. One group
reported that CD40 ligation could augment T-cell-independent serologic responses to pneumococcus antigens (8). Another group reported that immunization with DNA encoding
the CD40 ligand could enhance the immune response to respiratory syncytial virus DNA vaccines (32).
We report that the immune response to TCP peptides of
mice that have been immunized with intact TcpA can be modulated by class II MAb targeting of the TCP and two BRM, CT
and anti-CD40 MAb. The dynamics of the anti-TCP peptide
responses after immunization with intact TCP are remarkable
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FIG. 1. TcpA peptide sequences of antigens used in ELISA. Peptides 4, 5, and 6 were synthesized based on the predicted amino acid
sequences encoded by the classical biotype strain O395 TcpA gene.
Peptide lengths are 24-mer for TcpA, 25-mer for TcpA5, and 26-mer
for Tcp6. The overlaps between peptides 4 and 5 and 5 and 6 are
underlined.

and suggest that the immunogenicity of TCP depends on how
it is delivered.
MATERIALS AND METHODS
Animal manipulation. Young (8- to 12-week-old) female CBA/jNIA mice
were purchased from the National Institute of Aging colony. They were housed
in the Animal Resources Center at Dartmouth Medical School, where they were
provided with a TekLad rodent diet (Harlan, Madison, Wis.) and water ad
libitum. Three mice per group were anesthetized using Metofane (Mallinckrodt
Veterinary, Inc., Mundelein, Ill.) and groups A, B, and D were inoculated on the
right flank for subcutaneous (s.c.) injections with sterile solutions using tuberculin syringes fitted with a 27-gauge needle. For intranasal (i.n.) inoculations,
mice (group C) were anesthetized with Metofane and 10 l of antigen was
dripped into each nostril. A group is defined by a particular treatment modality;
for example, group A1 consists of mice immunized with TcpA alone and group
B1 consists of mice immunized with class II-targeted TcpA.
Blood collection at different time points in the experiments was performed on
anesthetized mice through the retro-orbital sinus. Initial immunizations were
performed on day 0, followed by serum collection to assess the primary responses
at day 21. Mice were immunized (groups A to D) s.c. with either 3 g of soluble
TCP (conjugated or not) at day 0 and either 1 g of CT or 1 g of CT plus 10
g of anti-CD40 MAb. Mice in groups A to C were boosted on day 28 s.c. with
5 g of whole TCP, while mice in group D were boosted intravenously (i.v.) via
the tail vein with 7.2 g of whole TCP on day 6 after the primary immunization.
All mice were bled on days 21 and 37 to assess the serologic response to TCP.
Conjugate and targeting-construct preparation. TCP was purified as described previously (27). Purified MAb FGK-44.5, an anti-murine CD40 MAb (a
gift from A. Rolnik, Basel, Switzerland) and MAb 10.2.16 (anti-class II MAb)
were produced in-house by protein A affinity chromatography (22). Anti-class II
MAb-TCP conjugates were produced essentially as described by Carayanniotis
and Barber (5). Briefly, TCP and protein A-purified anti-I-Ak MAb (10.2.16)
were replaced with biotin (Pierce Chemicals, Rockford, Ill.) and dialyzed against
phosphate-buffered saline (pH 7.4) overnight at 4°C before conjugation with
652.6 g of avidin (Sigma Chemical Co., St. Louis, Mo.). The molar ratio of
TcpA, antibody, and strepavidin used for these studies was 1:1:0.4, respectively.
The TCP–anti-class II MAb complexes were separated from free TCP by Sephadex G75 chromatography to yield a class II MAb targeting construct that was
confirmed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and
Western blotting (data not shown).
Serologic analysis. Ninety-six well enzyme-linked immunosorbent assay
(ELISA)/radioimmunoassay plates (Costar, Corning, N.Y.) were coated with 10
g of TCP peptide/ml in phosphate-buffered saline–0.04% sodium azide for 4 h
and then washed and stored at 4°C until used. TcpA peptide 4, peptide 5, and
peptide 6 (Fig. 1) were synthesized commercially and diluted in buffer for binding
to ELISA plates. Underlined sequences are areas where peptides have overlap
(peptide 4 to 5 and peptide 5 to 6). Serial twofold dilutions of experimental sera
(prebleed, primary [day 21], or secondary [day 37] antisera) or hyperimmune
positive-control sera were incubated in coated plates overnight at 4°C in blocking
buffer (BBS; 0.05% Tween 20, 1 mM EDTA, 0.25% bovine serum albumin,
0.04% sodium azide) at initial dilutions of between 1:100 and 1:200 for IgG
analysis or 1:25 for IgA analysis. Horseradish peroxidase-conjugated goat antimouse IgG, IgM, and IgA (serum Ig) or anti-IgG2a, anti-IgG1, and anti-IgA
MAb (KPL, Gaithersburg, Md., or Southern Biotechnology Associates, Inc.,
Birmingham, Ala.) were incubated at dilutions of 1:1,000 or 1: 5,000 in BBS
without sodium azide for 2 h at room temperature followed by extensive washing.
The color reaction was developed using ABTS (2,2⬘-azinobis[3-ethylbenzthiazolinesulfonic acid]; KPL, Gaithersburg, Md.) for 30 min and quantified using a
Molecular Devices (Menlo Park, Calif.) 96-well plate reader set to 405 nm. The
serum titer is reported as the reciprocal of the last dilution that was above zero

after subtracting twice the mean optical density values for blank background
wells. Prebleed sera were negative at the level of the background wells. As
reported, titers must differ by fourfold or more for the difference to be considered significant (12). In our laboratory, the typical standard deviation for TCP
ELISA titers that range from 100 to 100,000 is 37.08 ⫾ 46.16. If these values were
used to calculate the maximum titer bound by a particular confidence interval, a
titer of 100 that has added to it the mean standard deviation (37.1) plus two
standard deviations (92.2) of that mean would have an upper limit of 230.4. In
our studies, we would not consider this titer significantly different even though a
titer of 230 would account for 95% of the values that are possible from a
normally distributed population of titers. Our constraint for significance requires
that the titers differ by more than four standard deviations and thus represents
a conservative estimate of significant differences.

RESULTS
Serum Ab responses to TCP peptides 4, 5, and 6 is modulated by targeting and CT or CT and anti-CD40 MAb. Developing vaccines in ways that maximize responses to relevant
protective antigens is an important consideration, especially if
the protective antigen is not intrinsically immunodominant in
the context of the whole bacteria. We hypothesize that the
context of TCP with respect to the protein itself or other
immunodominant proteins of V. cholerae can influence the
serologic response directed at protective TCP epitopes.
Specific MAb conjugated with antigens have been used to
target antigen to surface molecules on APCs and have been
found to be an effective means to induce serologic responses
without adjuvants (5, 9, 24). Targeting antigen to selected
surface molecules provides signals to the APCs contemporaneous with antigen for more-effective immunization. To determine if the serologic response to TCP peptides could be manipulated, we targeted TCP to major histocompatibility
complex class II (MHC-II) molecules via anti-class II MAbTcpA conjugates. We also examined the additional effects of
other BRM, CT, and anti-CD40 MAb. These BRM function as
adjuvants for APC by modulating the APC presentation phenotype and/or the cytokine environment (3, 4, 8, 9, 12, 32).
CBA/jNIA mice were immunized, and the total serum antibody responses to TCP peptides 4, 5, and 6 were assessed
(Table 1). In Table 1, the corresponding groups are compared;
thus group A1 is compared to B1. The mice in groups A1 to A3
were treated with nontargeted TcpA and are always the control
for other comparisons of class II MAb-targeted TcpA with or
without other BRM.
Peptide 4 responses. Immunization of mice with nontargeted TCP (group A) does not induce a high-titer immune
response to peptide 4 at 21 or 37 days postimmunization. The
inclusion of CT or CT and anti-CD40 MAb provides for a
marginal response seen at day 37 for mice immunized with
nontargeted TCP compared to mice immunized with nontargeted TCP and no BRM. At 21 days, class II targeting of TCP
can induce a modest response to peptide 4 if CT is included in
the initial inoculum (group B2). Similar to that induced by
nontargeted TCP, the response to peptide 4 is not high, except
in one case at 37 days (group B2). Mice immunized i.n. with
class II MAb- targeted TCP (group C) did not respond unless
both CT and anti-CD40 MAb were included in the inoculum.
BRM modifiers were in general without effect if TcpA was
targeted by class II MAb after i.n. instillation. Targeting TCP
to class II MAb and providing CT and anti-CD40 MAb in the
initial inoculum with an i.v. TCP booster 6 days after the
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TABLE 1. Total serum anti-TCP peptide response to different TCP immunization methods
Titerc at indicated day for:
Groupb and treatment (subgroup)

A

B

C

D

Peptide 4

Peptide 5

21

37

TCP pure (A1)
TCP ⫹ CT (A2)
TCP ⫹ CT ⫹ anti-CD40 MAb (A3)

⬍100
⬍100
⬍100

⬍100
100
100

TCP/MHC-II conj (B1)
TCP/MHC-II conj ⫹ CT (B2)
TCP/MHC-II conj ⫹ CT ⫹ anti-CD40 MAb (B3)

⬍100
100
⬍100

TCP/MHC-II conj (C1)
TCP/MHC-II conj ⫹ CT (C2)
TCP/MHC-II conj ⫹ CT ⫹ anti-CD40 MAb (C3)
TCP/MHC-II conj (D1)
TCP/MHC-II conj ⫹ CT (D2)
TCP/MHC-II conj ⫹ CT ⫹ anti-CD40 MAb (D3)

21

Peptide 6
37

21

37

200
100
400

12,800
800
12,800

⬍100
200
100

⬍100
1,600
3,200

⬍100
1,600
100

⬍100
200
200

800
12,800
800

⬍100
800
100

400
400
800

⬍100
⬍100
100

6,400
⬍100
200

⬍100
⬍100
100

6,400
100
200

⬍100
⬍100
100

200
100
200

400
800
1,600

100
400
800

3,200
12,800
6,400

1,600
12,800
3,200

400
1,600
1,600

400
3,200
800

a

Serum antibodies (IgM, IgA, and IgG) are specific for anti-TcpA peptides 4, 5, and 6. Titers must differ by fourfold or more for the difference to be significant.
Groups A, B, and D received the primary immunization at day zero, s.c. Group C was immunized at day zero via i.n. instillation. Groups A to C were boosted s.c.
at day 28. Group D was boosted i.v. at day 6. Group A received nontargeted TCP, while groups B to D received class II MAb-targeted TcpA. TCP/MCH-II conj, TCP
targeted to MHC class II molecules via anti-class II MAb-TcpA conjugates.
c
The control for the comparisons is always group A to either B, C, or D. Titers in boldface represent titers that are significantly greater than those in the
corresponding control group (e.g., peptide 4, A2 versus B2 at day 21 or 37). The underlined titers are significantly less than those for the corresponding control group.
(e.g., peptide 5, A1 versus C1 at day 21).
b

primary immunization significantly boosted the anti-TCP peptide 4 response (group D compared to group A). (Titers from
day 21 or day 37 for group D should be compared only to the
day 37 titers of groups A to C, as they [groups D1 to D3]
received two doses of antigen before day 21, while at 21 days
groups A to C received one dose of antigen.) The titers of
group D mouse sera at days 21 and 37 were higher than those
of group A mouse sera at day 37. Providing an i.v. TCP antigen
boost at 6 days postimmunization is more effective than an s.c.
boost at day 21.
Peptide 5 responses. After 21 days, peptide 5 was immunogenic in the context of immunization with nontargeted TCP
(group A). The BRM, CT, and anti-CD40 MAb were without
significant effect for nontargeted TCP. Class II MAb-targeted
TCP (groups B and C) was not more effective at inducing an
anti-TCP peptide 5 response, as evidenced by a comparison of
day 21 titers with those of nontargeting TCP. Inclusion of other
BRM reduced the titers in groups B1 and C1 to C3 compared
to nontargeted-TCP responses. Compared to those from group
A, titers from groups B and C were generally low at day 37 with
two exceptions: C1 was similar to the group receiving no CT
and/or anti-CD40 MAb treatment and titers of B2 were higher
than those from the group receiving nontargeted TCP and CT.
Unlike what was found for peptide 4, where all treatments for
group D were superior to the corresponding treatments for
group A, targeting TCP to increase the anti-peptide 5 response
was only effective in treatment group D2. These data suggest
that for group D targeting TCP to class II MAb is not an
effective means to induce Abs to TCP peptide 5. It also indicates that the differences in the dose (5 g for group A versus

7.2 g for group D) of the boost do not impact the magnitude
of the subsequent serologic responses.
Peptide 6 responses. Immunization with nontargeted TCP
and BRM was the only means of inducing a modest antipeptide 6 response at day 21 that matured into a significant
response at day 37. Targeting TCP to class II molecules
(groups B and C) did not enhance the day 21 response to
peptide 6 except for group B2 when CT was used. Responses
at day 37 for groups B2 and B3 and C2 and C3 (targeted TCP
and CT or CT and anti-CD40 MAb, respectively) were lower
than those in mice immunized with nontargeted TCP and the
BRM. This is in contrast to what was found for groups B1 and
C1, which had a significant response (day 37) compared to
group A1. Group D, which received the i.v. TCP boost, had an
enhanced response to peptide 6 only if class II MAb targeting
was not accompanied by other BRM treatment. While the
response of group D mice that were given CT and anti-CD40
MAb was not different from the response for equivalent treatments in group A, the response of group D mice to peptide 6
compared to responses to targeted TCP of groups B and C,
which also received one or both of those BRM, was enhanced
in selected cases. This was apparent in group C (day 37), which
received CT alone or both CT plus anti-CD40 MAb (D2 and
D3 versus C2 and C3). These data suggest that targeting of
antigen in the context of other BRM generally has a detrimental effect on serologic response to TCP peptide 6 unless a day
6 i.v. boost is provided.
IgG1, IgG2a, and IgA responses to TCP are modulated by
targeting and BRM. We examined the sera for anti-TCP peptide responses that are indicative of either a Th1 (IgG2a), a
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TABLE 2. Anti-TCP isotype and subclass responses and peptide specificitya
Titerc at indicated day and Ig for:

Groupb and treatment
(subgroup)

A

B

C

D

Peptide 4
21

Peptide 5
37

21

Peptide 6
37

21

37

IgG1 IgG2a IgA IgG1 IgG2a IgA

IgG1 IgG2a IgA

⬍25 ⬍25 ⬍25 25
⬍25 ⬍25 ⬍25 125

25
25

25
25

⬍25 ⬍25 ⬍25
⬍25 ⬍25
25

125
125

125
125

125 ⬍25 ⬍25 ⬍25
25 25
25 ⬍25

125 25
625 125

25
25

25 ⬍25 ⬍25 125

125

125

125 ⬍25 ⬍25

625

625

250 125 ⬍25 ⬍25 3,125 625

126

25 125
25 625

25
125

25
25

⬍25 ⬍25 ⬍25 125
125 ⬍25 250 3,125

125
125

25
250

25 125

25

25

TCP/MHC-II conj (C1)
⬍25 ⬍25
25 125
TCP/MHC-II conj ⫹ CT (C2) 125 ⬍25
25 625
TCP/MHC-II conj ⫹ CT ⫹
anti-CD40 MAb (C3)
⬍25 ⬍25 ⬍25 25

125
25
25

25 ⬍25 ⬍25 125
125 ⬍25 125 125

25
125

TCP pure (A1)
TCP ⫹ CT (A2)
TCP ⫹ CT anti-CD40
MAb (A3)

TCP/MHC-II conj (B1)
⬍25 ⬍25
TCP/MHC-II conj ⫹ CT (B2) 125 ⬍25
TCP/MHC-II conj ⫹ CT ⫹
anti-CD40 MAb (B3)
125 ⬍25

TCP/MHC II conj (D1)
TCP/MHC II conj ⫹ CT (D2)
TCP/MHC II conj ⫹ CT ⫹
anti-CD40 MAb (D3)

25 ⬍25

25 125

625

125 ⬍25

IgG1 IgG2a IgA IgG1 IgG2a IgA IgG1 IgG2a IgA

25 ⬍25 ⬍25
25
25
25

125

625

125

250 125 ⬍25

25
25

⬍25 ⬍25 ⬍25
⬍25 ⬍25 ⬍25

125
625

125
25

25 ⬍25 ⬍25 ⬍25
125 ⬍25 ⬍25
25

⬍25

⬍25 ⬍25 ⬍25

25

25

25 125
25 3,125

125
625
625

⬍25 125
125 3,125
25

125

125
125

125 ⬍25

125

25

125 125
625 125

25
25

625 125

25

125
125

25
25

⬍25
25

25

25

25

⬍25 ⬍25 ⬍25 ⬍25
25 ⬍25 ⬍25
25

25 25
625 625

25
125

25 ⬍25 ⬍25 ⬍25

25 125

⬍25

⬍25 ⬍25 ⬍25

25

a

IgG1, IgG2, and IgA titers are specific for anti-TcpA peptides 4, 5, and 6. Titers must differ by fourfold or more for the difference to be significant.
Groups A to D and TCP/MHC-II conj are as defined for Table 1.
The comparisons are always to members of group A and within a subgroup of that group, e.g., A1 to B1 or A3 to C3. Titers in boldface represent titers that are
significantly greater than those in the corresponding control group (e.g., peptide 4, A2 versus B2 at day 21 or 37; IgG1 and IgA). The underlined titers are significantly
less than those for the corresponding control group (e.g., peptide 5, A3 versus C3 for 21 day titers. IgG1).
b
c

Th2 (IgG1), or an IgA response (serum IgA to determine if the
difference in serologic responses between the groups was regulating isotype and subclass responses). The data in Table 2
suggest that at day 21 IgG1 and IgA benefited from targeting
TCP and the inclusion of CT and/or anti-CD40 MAb. IgG2a
was elevated in some groups (B2, C1, and D2 and D3) later in
the response.
Peptide 4 responses. Immunization with intact TCP did not
lead to detectable IgG1, IgG2a, or IgA responses 21 days after
primary s.c. immunization, except in groups B and C (both
class II MAb-targeted TCP), as is most notably evident in the
mice that were also given CT (groups B2 and C2) or CT and
anti-CD40 MAb (group B3). In the groups (B2, C2, and D2)
that were immunized with anti-class II MAb-targeted TCP and
CT, the mice responded in general with a modest increase in
serum IgA compared to the response to the nontargeted antigen (group A2). Consistent with the lack of response to immunization with whole TCP, mice immunized with targeted
TCP with or without other BRM did not generate an anti-TCP
peptide 4 IgG2a Ab (day 21), which is indicative of a lack of
stimulation of a Th1-type serologic response. Targeting TCP
with anti-class II MAb and providing CT or CT and anti-CD40
MAb increased the IgG1 response significantly over that to
nontargeted TCP at day 37 in selected subgroups for which the
method of immunization and boost varied.
Group D mice (day 21 group D versus day 37 group A) had
variable anti-peptide 4 responses compared to group A. If both
CT and anti-CD40 MAb or neither was included in the immu-

nization, the IgG1, IgG2a, and IgA titers were lower in all but
one of the targeted-TCP group. The use of CT alone in group
D results in similar responses to those seen in group A2. After
several weeks (day 37), the lack of response in group D, which
received CT and anti-CD40 MAb, is only apparent in the IgA
antipeptide response (D1 and D2) and interestingly the IgG2a
response becomes greater than that seen for groups A1 and
A2.
The differences noted in the response to peptide 4 (group B)
at 21 days that were dependent on the targeting of TCP and
other BRM were variable at 37 days. In group B3 the responses
were normalized to or were lower than those in group A3. In
group B, class II MAb targeting of TcpA by the s.c. route
generally increased the IgG1 titers (days 21 and 37) but was
without effect on the IgA titers (day 37). Anti-CD40 MAb
administration (group B3) had a negative effect on the IgG2a
and IgA titers at day 37. A pattern of responses similar to that
for group B was seen if the TCP was delivered by anti-class II
MAb i.n. In group C3, the anti-CD40 MAb diminished the
serologic response at day 37 for all isotypes and subclasses
examined.
Immunization with anti-class II MAb-targeted TCP followed
by an i.v. boost with antigen 6 days after the initial antigenic
exposure shifted the response (day 37) to IgG2a but diminished the IgA response in two out of three subgroups. As
reported in Table 1, targeting TCP to class II MAb induced a
response to peptide 4 at 21 days, which was maintained at day
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37. This difference was not as apparent when only total serum
anti-TCP peptide 4 responses were examined.
Peptide 5 responses. The individual subclass and isotype
responses (day 21) to peptide 5 were low or absent in mice
immunized with nontargeted TCP. BRM was not regularly
effective at modulating the anti-peptide 5 response to nontargeted TCP. TCP targeted to class II molecules with CT and/or
anti-CD40 MAb included in the inoculum significantly affected
the IgG1 titers and IgA titers (compare B2 and B3 to A2 and
A3). Targeting TCP to class II MAb via i.n. instillation was
generally ineffective or detrimental to the anti-peptide 5 response, as evidenced by the day 21 titers. However, group C
sera at 37 days contained an anti-peptide 5 response that was
variable compared to sera of the equivalent subgroup in group
A. CT with i.n. instillation of class II MAb-targeted TCP enhanced the IgG1 and IgA responses at day 37. Again, the
inclusion of anti-CD40 MAb in the primary immunization
(group C3) reduced the response to TCP peptides.
Similar to what was found for peptide 4, the TCP boost at 21
days increased the anti-TCP peptide 5 response at 37 days
postimmunization. The anti-TCP peptide 5 IgG1 (B2 and B3,
125; A2, 125) and IgA (B2, 250; A2, 25) responses at day 37
postimmunization were higher in mice immunized with targeted antigen and CT than in group A mice that had been
given nontargeted TCP and CT. Comparing the day 37 responses for group A and the day 21 response for group D
reveals a variable response depending on the BRM. There was
a large increase in the IgG1 anti-TCP peptide 5 Ab (group
D2), but the other comparisons were generally not different
except for those concerning group D3, the response in which
was decreased if anti-CD40 MAb and CT were included at the
primary immunization followed by a day 6 i.v. boost. Groups C
and D did not consistently sustain the IgA titers, unlike groups
A and B.
Peptide 6 responses. Immunization with intact, nontargeted
TCP was more immunogenic for peptide 6 responses at day 21
than anti-peptide 4 or 5 responses. Targeting TCP to class II
MAb increased the IgA response at 21 days if CT or CT and
anti-CD40 MAb were included in the primary inoculum. The
IgG1 response to peptide 6 was reduced in groups C2 and C3
and D2 and D3 compared to the response reported for groups
A2 and A3. The IgG2a response at day 21 to peptide 6 was
generally absent from groups C and D. Compared to what was
found for the anti-peptide 4 and 5 responses following targeted
TCP immunization, the anti-class II MAb targeting on day 21
did not enhance the serologic response in the IgG compartment but did maintain the capacity to induce some anti-peptide 6 IgA responses.
The magnitudes of the responses to peptide 6 at day 37 in
mice immunized with nontargeted TCP (group A) were similar
to those of the anti-peptide responses (group A) to peptides 4
and 5. This is in contrast to the response at 37 days of mice
immunized with targeted TCP. Targeting TCP to class II molecules was less efficacious for the anti-peptide 6 response for
groups B to D than using nontargeted TCP. In general, the
anti-peptide 4 and 5 responses of groups B to D were superior
to the anti-peptide 6 response at day 21 or 37. Group D mice
with one exception (D3; IgA) respond to peptide 6, and the
responses are generally low at day 37 for group D. As seen with
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TABLE 3. Increase or decrease in anti-TCP peptide titersa
Group (treatment)

No. of responses of 18 tested
(%) showing:
Increase in titer

Decrease in titer

Standard
6 (33.3)

Standard
1 (5.5)

11 (61.1)

0 (0.0)

B1 (class II targeted)
B2 (class II targeted, CT)
B3 (class II targeted, CT,
anti-CD40 MAb)

4 (22.2)
9 (50.0)

1 (5.5)
0 (0.0)

4 (22.2)

6 (33.3)

C1 (class II targeted)
C2 (class II targeted, CT)
C3 (class II targeted, CT,
anti-CD40 MAb)

3 (16.6)
6 (33.3)

2 (11.1)
6 (33.3)

1 (5.5)

12 (66.7)

D1 (class II targeted)
D2 (class II targeted, CT)
D3 (class II targeted, CT
anti-CD40 MAb)

1 (5.5)
8 (44.4)

9 (50.0)
3 (16.6)

1 (5.5)

15 (83.3)

A1 (nontargeted)
A2 (nontargeted, CT)
A3 (nontargeted, CT,
anti-CD40 MAb)

a

The individual groups for a given treatment from Table 2 were tabulated
based on an increase in the anti-TCP peptide titer or a decrease in the anti-TCP
peptide titer. The percent effect was calculated based on 18 different group
responses to a group treatment. The comparison was made either to the common
regimen, A1 to B1, A1 to C1, etc., or, for group A, A1 to A2 and then A1 to A3.
The majority of the comparisons of effects within the group, i.e., B1 to B2 or B2
to B3, provide information relative to the effect of the BRM, CT, and anti-CD40
MAb. Comparisons between the groups account for the method of immunization.

groups A to C, CT was effective at either maintaining or enhancing the response of group D2 mice.
Effect on anti-peptide 4, 5, and 6 TCP responses correlates
with the type of immunization and BRM treatment. Given the
multiple comparisons possible with the data in Table 2, we
attempted to simplify the analysis by comparing the IgG1,
IgG2a, and IgA responses of groups B to D to those of group
A but only within a given treatment modality, e.g., B1 to A1,
i.e., mice given TCP targeted or not without BRM. For the
comparisons within group A, the anti-TCP serologic response
without targeting or other BRM (group A1) was compared to
those for nontargeted TCP and either CT or CT and antiCD40 MAb (A2 and A3, respectively; Table 3).
The serologic response for nontargeted TCP with CT
(33.3% of the anti-TCP peptide responses increased) or CT
plus anti-CD40 MAb (61.1% of the anti-TCP peptide responses increased) was increased. The effect of class II MAb
targeting and other BRM was both positive and negative. Class
II MAb-targeted TCP was more effective at inducing responses
than nontargeted TCP. The s.c. delivery of class II MAbtargeted immunogen was comparable to i.n. (group C) delivery, and both were superior to s.c. primary immunization and
i.v. boost (group D). If CT was included in the immunizing
inoculum with class II MAb-targeted TcpA, the anti-TCP peptide titers were further increased: B2 versus B1, 50.0 versus
22.2%, respectively; C2 versus C1, 33.3 versus 16.6%, respectively; D2 versus D1, 44.4 versus 5.5%, respectively. The i.v.
boost was approximately fourfold less effective (group B to
group D) than the s.c. boost if class II MAb-targeted TCP was
first provided s.c. Similarly, when D3 was compared to B3, it
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was found that the response was again about fourfold lower in
the i.v.-boosted group. The use of CT with targeted or nontargeted TcpA clearly enhanced the anti-TcpA response of mice
to TcpA peptides 4, 5, and 6. However, the positive response
induced by the CT treatment can be mitigated by the addition
of anti-CD40 MAb to the immunization regimen. The CD40
effect lowers the serologic response to either what was obtained with just class II MAb-targeted TcpA alone or in one
case (C3) below what is seen with class II MAb-targeted TcpA.
Interestingly, in nontargeted TCP, anti-CD40 MAb did not
decrease any of the titers and in 61% of the cases improved the
response. It is apparent that adding anti-CD40 MAb to the
immunization significantly affects the serologic response in
multiple groups, but in a negative manner for the class II
MAb-targeted TCP. The rank order of the negative effect of
anti-CD40 MAb treatment of TcpA peptide titers was D3
(83%), C3 (67%), and B3 (33%). Clearly, the route of immunization of class II MAb-targeted TCP is related to the effect
that the anti-CD40 MAb has on the anti-TcpA peptide titers.
DISCUSSION
Cholera is an enteric disease caused by V. cholerae infection.
The current killed-whole-cell and attenuated-live cholera vaccines have differential efficacy depending on the target population and the time after vaccination and primary infection
(11). The killed-whole-cell vaccines do not protect as long as is
desirable. The live-attenuated vaccines work well in North
Americans but have not been demonstrated to protect those in
areas where cholera is endemic (11). Several antigens that are
thought to induce protection against cholera infection include
lipopolysaccharide, CT, TCP, and outer membrane proteins
(13, 14, 21, 26).
TCP or peptides derived from it can induce protective responses in animals (27–29, 34). Their utility as immunogens in
the context of live-whole-cell and killed-whole-cell cholera vaccines is unproven. Multiple exposures of individuals in areas of
endemicity can result in seroconversion to TCP (13). The issues that compromise TCP immunogenicity in the context of
whole-cell vaccines could relate to (i) availability or the
amount of the TCP antigen in the vaccines and (ii) its immunogenicity (B- and T-cell epitopes), both intrinsic and in the
context of other immunodominant antigens. There is an evolving literature that documents changes in the immune response
to protein antigens when BRM are added to an immunization
regimen. In our system, we focused on targeting antigen to
class II molecules and inclusion of CT or anti-CD40 MAb as a
means to modify anti-TCP responses. Class II MAb targeting is
a well-documented method (5, 9, 24, 25) to enhance the immunogenicity of targeted proteins. Our results clearly indicate
that class II MAb-targeting TCP and/or other BRM can influence the isotype of the Ab response as well as the magnitude
of the response to TCP peptides. The mechanism of the effect
of class II MAb targeting of antigen is not known. Increased
access of targeted antigen to DCs and perhaps signals from
class II molecules that upregulate costimulatory molecules
CD80 or CD86 could enhance the presentation capacity of the
APCs (20). Class II MAb signaling also increases tumor necrosis factor alpha (TNF-␣) and interleukin-6 (IL-6), both of

which can affect maturation and antigen processing of immature DCs (1, 7, 23, 35).
BRM such as CT or CD40 signaling can influence the efficiency of T-cell activation and Ab production by regulating
substrates (MHC-II peptide) and cytokines for clonal activation of both B and T cells (19, 33). CT is an adjuvant that has
been shown to increase the IgA responses to coinjected antigens targeted to class II molecules (3, 4, 25). CD40 ligation is
known to enhance APC function for a number of antigens (8,
10, 15, 32). In vivo CD40 can mature DCs to increase their
effectiveness as APC by stimulating the processing of antigen
and the charging of class II MAb with peptides (Frleta and
Wade, unpublished observations). CD40 ligation can enhance
expression of CD54, CD80, CD86, and class II molecules.
CD40 stimulation enhances secretion of tumor necrosis factor
alpha, IL-1␤, IL-12, and IL-6.
The mechanism whereby class II MAb targeting and CT or
CT and anti-CD40 MAb treatment modulates anti-TcpA peptide responses is not known. The potential dynamics of BRM
manipulations are perhaps illustrated by IL-6, a cytokine made
in response to class II MAb targeting, and the other BRM.
IL-6 can regulate the processing of hen egg lysozyme in DCs
(7). Normally, immunodominant binding peptides are processed in DCs, but, if IL-6 is added, the immunodominant
peptides are no longer generated and cryptic peptides are now
expressed on class II MAb. One hypothesis consistent with this
model is that TCP normally has immunodominant peptides
that do not focus T-cell help to optimally activate B cells
during infection or immunization with whole cells. Consistent
with the immunorecessive hypothesis is the possibility that the
conjugation of antigens such as TcpA to anti-class II MAb
affects the “conformation” of TcpA and thus can modulate its
processing and thus its presentation. This effect may be manifested as the generation of new class II MAb-peptide complexes or as increased levels of TcpA immunodominant peptides that would now be stimulatory. The differential induction
of effector Th1 versus Th2 cells based on the amount or type of
peptide expressed can regulate the type of Ab generated (reference 30 and references therein).
The mechanism whereby antigen targeting or BRM can
change the serologic response to B-cell epitopes (serologic
response to peptides 4 to 6) that can either enhance a B-cell
response, as for peptide 4, or reduce the response, as for
peptide 6, is more complex. B-cell epitopes that provide for Ig
ligation and subsequent B-cell activation can be provided by
DCs (36). Thus targeting antigen to DCs and the “downstream” effects this would have on the handling of antigen may
differentially expose B-cell epitopes or affect the longevity of
presentation, both of which would affect subsequent B-cell
activation. Alternatively, class II MAb-targeted TCP may target TCP peptide-specific B cells directly and thus make certain
anti-TCP peptide responses more effective.
These data illustrate the potential to modulate the immune
response to TcpA. In general, anti-class II MAb-targeted TCP
induced higher (IgG1 and IgA) responses but had marginal
effects on IgG2a in most of the groups at the early time points;
these effects could be overcome later in the response. CT
enhanced the serum IgG1 and IgA responses for certain peptides. We did not measure secretory IgA in this study. However, it is not clear which isotype is the most protective against
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cholera in humans. The ability to select appropriate B cells that
respond to TcpA peptides 4 and 5 is the limiting element in
cholera vaccine development, not devising routes of immunization. Serologic responses to TCP peptides 4 to 6 were not
equally affected by the various treatments. Even with other
BRM treatment, peptide 6 was not particularly immunogenic if
TCP was targeted by class II MAb, but peptide 4 was if CT was
added. This is an important observation, as peptide 4 has been
shown previously to be the most protective immunogen among
peptides 4 to 6 (29).
The responses to TCP could be negatively or positively regulated by anti-CD40 MAb. The positive effect of anti-CD40
MAb was restricted to the nontargeted TCP, while the negative
effect of anti-CD40 MAb was seen in the class II MAb-targeted
TCP groups. The reason for this is likely related to the number
of events at the level of APC that regulate antigen presentation. These events are simplified in the nontargeted TCP group
compared to the class II MAb-targeted groups. APCs do not
have to accommodate class II MAb and CT signaling along
with the CD40 signaling in the nontargeted TCP group.
The mice that were immunized with CT and anti-CD40
MAb in the context of class II signaling induced by class II
MAb-targeted TCP had a restrictive serologic response to the
TcpA peptides. That was evident in anti-peptide 4, 5, and 6
responses but seemed to be centered on the anti-peptide 6
responses and also on the responses to all peptides in groups C
and D. The difference between groups C and D and group B is
the site of immunization, i.n. for group C, and the timing and
physiological context of the TCP boost for group D, 6 days i.v.
versus 21 days s.c. The mechanism by which CD40 ligation
results in lower serologic responses is not known, but we have
noted the lower response of mice immunized with antigen and
anti-CD40 MAb (12). We speculate that this is due to the
maturing effect of CD40 ligation on DCs (23). If DCs are
matured too quickly, the ability to internalize membrane receptors and bound antigen is reduced and thus targeted class II
MAb may not effectively be internalized for maximal generation of MHC-II peptide complexes. This would clearly affect
the T-cell compartment. It is also formally possible that the
anti-CD40 MAb is disruptive of the effective cognate interaction of B and T cells. We do not favor this as a universal
explanation because, when TcpA is not targeted, the antiCD40 MAb enhances the serologic response. A direct effect of
CD40 ligation may involve B-cell death early in the immunization period. The anti-CD40 MAb activates B cells initially;
this is followed by their loss from the cell population in the
spleen of anti-CD40 MAb-treated mice (D. Frleta and W. F.
Wade, personal observation). The negative CD40 effect on B
cells is perhaps amplified by the anti-class II MAb targeting,
which is also known to kill B cells. These negative signals are
known to be influenced by surface Ig engagement.
These data support our hypothesis that the mode and the
“contextual” mechanism of antigen administration can drive
differential TCP peptide responses. If we can determine which
TCP B-cell epitopes are the most protective, having the ability
to manipulate the immune response to focus on that epitope
would be an effective vaccine strategy. It is not clear that the
experimental manipulations we have used to uncover the dynamics of TcpA presentation are directly applicable to humans. Human APCs are clearly targets for class II MAb-tar-
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geted antigens, but CT and anti-CD40 MAb are potentially too
reactive for use in humans. In humans, other manipulations,
such as directing specific peptides to APCs with cytokine treatment, may mimic the dynamics of class II MAb targeting of
TcpA and other BRMs we report here.
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